Učitavanje...
Anti-HER2/Neu passive-aggressive immunotherapy
Preclinical studies have established that CD8(+) T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER2/Neu the...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Landes Bioscience
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3935925/ https://ncbi.nlm.nih.gov/pubmed/24605268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.27296 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|